Leios Therapeutics
PrivateLast Round
Strategic
Aug 30, 2026
Total Funding Raised
$2.47M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Leios Therapeutics operates in Healthcare & Life Sciences and is based in La Jolla, California. Its latest recorded funding round was a Series B round in August 2021.
Leios Therapeutics is a clinical-stage biotechnology company that develops innovative injectable therapies for aesthetic indications, including focal fat reduction and body contouring.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Fashion & Beauty, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Leios Therapeutics Comparables
Compare Leios Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sagesse Bio, Inc. | 86% | |
| AMI Pharm Co., Ltd. | 85% | |
| Raziel Therapeutics | 83% |
For institutional investors. Book with your work email.
Leios Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Aug 30, 2026 | ||||
| Strategic | Jan 26, 2026 | ||||
| Series B | Aug 23, 2021 | ||||
| VC Round | Apr 19, 2018 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 30, 2026
China Medical System Holdings Limited participated in the round.
- Jan 26, 2026
BNC Korea Co. Ltd participated in the round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 14, 2026
Leios Therapeutics partners with Bnc Korea through an exclusive regional licensing and strategic investment agreement covering South Korea, with Bnc Korea assuming development costs in the territory in 2026.
- partners_withAug 31, 2026
Leios Therapeutics partners with CMS International Development And Management Limited under an exclusive agreement for CMS International Development And Management Limited to develop, manufacture, and commercialize 10XB-101 in China, with Leios Therapeutics receiving upfront, milestone, and royalty payments and supporting clinical development, on Aug 30th '26.
For institutional investors. Book with your work email.
Leios Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Leios Therapeutics's valuation, stock price, and market status.
Is Leios Therapeutics a public or private company?
Leios Therapeutics is a private company.
What is the current stock price of Leios Therapeutics?
Leios Therapeutics is a private company, so its shares have no public market price. Caplight tracks Leios Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Leios Therapeutics worth (valuation)?
Valuation information for Leios Therapeutics is not publicly available.
Can I buy Leios Therapeutics stock?
Leios Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Leios Therapeutics's last funding round?
Leios Therapeutics's most recent funding round was Strategic on August 30, 2026.
Who are the main investors in Leios Therapeutics?
Investor information for Leios Therapeutics is not publicly disclosed.
Will Leios Therapeutics IPO soon?
No public IPO plans have been announced for Leios Therapeutics.
How can I track Leios Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Leios Therapeutics's shares on secondary markets.